Biotech cites federal review of deal with Chinese firm in latest staff cuts
The company faces a challenging fundraising environment and an ongoing federal review of its deal to sell manufacturing assets to a Chinese company.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Hannah Green Source Type: news
More News: Biotechnology | China Health | Environmental Health | Fundraising | Health Management | Pharmaceuticals